Efficacy gap between phase II and subsequent phase III studies in oncology

類似資料

• Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
  著者:: Vreman, Rick A., 等
  出版事項: (2018)
• Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
  著者:: A Vreman, Rick, 等
  出版事項: (2020)
• Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
  著者:: Vreman, Rick A., 等
  出版事項: (2019)
• The Application and Implications of Novel Deterministic Sensitivity Analysis Methods
  著者:: Vreman, Rick A., 等
  出版事項: (2020)
• Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe
  著者:: Vreman, Rick A., 等
  出版事項: (2020)